The U.S. Food and Drug AdministrationbizWatch U.S. Food and Drug Administration granted Orphan Drug Designation to Revimmune, Accentia Biopharmaceuticals Inc.bizWatch Accentia Biopharmaceuticals Inc.'s planned therapy to treat autoimmune diseases including multiple sclerosis.
With FDA Orphan Drug status, Accentia, based in Tampa, gains seven years of market exclusivity for Revimmune for systemic sclerosis and autoimmune hemolytic anemia upon its approval by the FDA, a company statement said.
Last week, Accentia (OTCQB: ABPI) said it had entered into a definitive financing agreement for $4 million to support the development of Revimmune.